Literature DB >> 35066152

AAPOS uniform guidelines for instrument-based pediatric vision screen validation 2021.

Robert W Arnold1, Sean P Donahue2, David I Silbert3, Susannah Q Longmuir4, Geoffrey E Bradford5, Mae Millicent W Peterseim6, Amy K Hutchinson7, James W O'Neil8, Alejandra G de Alba Campomanes9, Stacy L Pineles10.   

Abstract

BACKGROUND: As instrument-based pediatric vision screening technology has evolved, the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) has developed uniform guidelines (2003, updated 2013) to inform the development of devices that can detect specified target levels of amblyopia risk factors (ARFs) and visually significant refractive error. Clinical experience with the established guidelines has revealed an apparent high level of over-referral for non-amblyopic, symmetric astigmatism, prompting the current revision.
METHODS: The revised guidelines reflect the expert consensus of the AAPOS Vision Screening and Research Committees.
RESULTS: For studies of automated screening devices, AAPOS in 2021 recommends that the gold-standard confirmatory comprehensive examination failure levels include anisometropia >1.25 D and hyperopia >4.0 D. Astigmatism >3.0 D in any meridian and myopia < -3 D should be detected in children <48 months, whereas astigmatism >1.75 D and myopia < -2 D should be detected after 48 months. Any media opacity >1 mm and manifest strabismus of >8Δ should also be identified. Along with performance in detecting ARFs and refractive error, validation studies should also report screening instrument performance with regard to presence or absence of amblyopia. Instrument receiver operating characteristic curves and Bland-Altman analysis are suggested to improve comparability of validation studies.
CONCLUSIONS: Examination failure criteria have been simplified and the threshold for symmetric astigmatism raised compared to the 2013 guidelines, whereas the threshold for amblyogenic anisometropia has been decreased. After age 4 years, lower magnitudes of symmetric astigmatism and myopia are also targeted despite a low risk of amblyopia, because they can influence school performance and may warrant consideration of myopia prevention therapy.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35066152     DOI: 10.1016/j.jaapos.2021.09.009

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  5 in total

1.  Pediatric Non-Refractive Vision Screening with EyeSwift, PDI Check and Blinq: Non-Refractive Vision Screening with Two Binocular Video Games and Birefringent Scanning.

Authors:  Tsaina Mahlen; Robert W Arnold
Journal:  Clin Ophthalmol       Date:  2022-02-11

2.  Instrument Referral Criteria for PlusoptiX, SPOT and 2WIN Targeting 2021 AAPOS Guidelines.

Authors:  Robert Arnold; David Silbert; Heather Modjesky
Journal:  Clin Ophthalmol       Date:  2022-02-25

3.  Multifaceted Amblyopia Screening with blinq, 2WIN, and PDI Check.

Authors:  Robert Arnold; Mario Angi
Journal:  Clin Ophthalmol       Date:  2022-02-15

4.  Comparative Validation of PlusoptiX and AI-Optic Photoscreeners in Children with High Amblyopia Risk Factor Prevalence.

Authors:  Robert W Arnold
Journal:  Clin Ophthalmol       Date:  2022-08-16

5.  Instrument referral criteria for PlusoptiX and SureSight based on 2021 AAPOS guidelines: A population-based study.

Authors:  Qi Yan; Rui Li; YingXiao Qian; Xiao Lin; Hui Zhu; Yue Wang; Xiaoyan Zhao; Xiaohan Zhang; Qigang Sun; Qingfeng Hao; Haohai Tong; Yue Zhu; Zhitong Li; Yan Zhu; Hu Liu; Dan Huang
Journal:  Front Public Health       Date:  2022-09-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.